Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Cash from Operations (2016 - 2025)

Outlook Therapeutics (OTLK) has disclosed Cash from Operations for 7 consecutive years, with 14939111.0 as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Operations fell 36.21% to 14939111.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 55801213.0, a 64.65% decrease, with the full-year FY2025 number at 51829437.0, up 24.66% from a year prior.
  • Cash from Operations was 14939111.0 for Q4 2025 at Outlook Therapeutics, down from 12377197.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 10967335.0 in Q4 2024 to a low of 16583746.0 in Q1 2025.